Use of Oral JAK Inhibitors and a TYK2 Inhibitor in the Treatment of Psoriasis–Eczema Overlap ( PsEma ): A Retrospective Study
- 10 April 2026
- journal article
- Published by Wiley in International Journal of Dermatology
- Vol. 65 (8) , 1792-1794
Abstract
No abstract availableKeywords
This publication has 5 references indexed in Scilit:
- Unravelling the Mystery of Psoriasis Dermatitis (PsoDermatitis): A Practical Guide to Recognition and ManagementJournal of Clinical Medicine, 2025
- Efficacy of Janus kinase inhibitors in the treatment of psoriasiform atopic dermatitisClinical and Experimental Dermatology, 2024
- Management of Patients Affected by Moderate-to-Severe Atopic Dermatitis with JAK Inhibitors in Real-World Clinical Practice: An Italian Delphi ConsensusDermatology and Therapy, 2024
- Application of JAK inhibitors in paradoxical reaction through immune-related dermatosesFrontiers in Immunology, 2024
- Atopic dermatitis and psoriasis: two different immune diseases or one spectrum?Current Opinion in Immunology, 2017